Premature menopause in patients with systemic lupus erythematosus: risk factors, role of cytostatic therapy
- Authors: Serikova S.Y.1, Kozlovskaya N.L1, Bobkova I.N1
-
Affiliations:
- Issue: No 5 (2013)
- Pages: 48-52
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/261907
- ID: 261907
Cite item
Abstract
Risk factors and pathogenesis of premature menopause in patients with systemic lupus erythematosus with special emphasis on drug gonadotoxicity are reviewed.
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
References
- Blumenfeld Z., Halachmi Sar’el, Alik Peretz B. et al. Premature ovarian failure — the prognostic application of autoimmunity on conception after ovulation induction // Fertil Steril. — 1993; 59:76-81.
- Shuster L.T., Rhodes D.J., Gostout B.S. et al. Premature menopause or early menopause: long-term health consequences//Maturitas. — 2010; 65(2): 161.
- Carp H.J.A., Selmi C., Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss// Journal of Autoimmunity. — 2012; 38: J266—J274.
- Baba S., Katsumata Y, Kawaguchi Y. et al. Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: A case-control study // BMC Women's Health. — 2011; 11:28. doi: 10.1186/1472-6874-11-28.
- Medeiros M.M.C., Silveira V.A.L., Menezes A.P.T. et al. Risk factors for ovarian failure in patients with systemic lupus erythematosus // Braz J Med Biol Res. — 2001; 34(12):1561—1568.
- Fatnoon N.N.A., Azarisman S.M.S., Zainal D. Prevalence and risk factors for menstrual disorders among systemic lupus erythematosus patients // Singapore Med J. — 2008; 49 (5): 413.
- Gonzalez L.A., McGwin G.Jr., Duran S. et al. Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII) for the LUMINA Study Group // Ann Rheum Dis. — 2008; 67:1170—1173.
- Ioannidis J.P.A., Katsifis G.E., Tzioufas A.G. et al. Predictors of Sustained Amenorrhea from Pulsed Intravenous Cyclophosphamide in Premenopausal Women with Systemic Lupus Erythematosus // J Rheumatol. — 2002; 29:2129—2135.
- Biscotti C.V., Hart W.R. and Lucas J.G. Cystic enlargement resulting from autoimmune oophoritis //Obstet Gynecol. — 1989; 74:492—495.
- Kalantaridou S.N., Braddock D.T., Patronas N.J. et al. Treatment of autoimmune premature ovarianfailure: Case report//Hum. Reprod. — 1999; 14(7):1777—1782.
- Cowchock F.S., McCabe J.L., Montgomery B.B. Pregnancy after corticosteroid administration in premature ovarian failure (polyglandular endocrinopathy syndrome) // Am J Obstet Gynecol. — 1988; 158(1):118—119.
- Kasteren Y.M. van, Braat D.D.M., Hemrika D.J. et al. Corticosteroids do not influence ovarian responsiveness to gonadotropins in patients with premature ovarian failure: a randomized, placebo-controlled trial // Fertil Steril. — 1999; 71(1): 90—95.
- Chiauzzi V., Cigorraga S., Escobar M.E. et al. Inhibition of follicle-stimulating hormone receptor binding by circulating immunoglobulins // J Clin Endocrinol Metab. — 1982; 54:1221—1228.
- Moncayo H., Moncayo R., Benz R. et al. Ovarian failure and autoimmunity. Detection of autoantibodies directed against both the unoccupied luteinizing hormone/human chorionic gonadotropin receptor and the hormone-receptor complex of bovine corpus luteum // J Clin Invest. — 1989; 84:1857—1865.
- Pasoto S.G., Viana V.S., Mendonca B.B. et al. Anticorpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus?// J Rheumatol. — 1999; 26:1087-1093.
- Tang V.W., Faiman C. Premature ovarian failure: a search for circulating factors against gonadotropin receptors// Am J Obstet Gynecol. — 1983; 146:816-821.
- Novosad J.A., Kalantaridou S.N., Tong Z.B. et al. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation // BMC Womens Health. — 2003; 3:2.
- Cabral de Sousa C.D., das Chagas Medeiros M.M., Trindade Viana V.S. et al. Anticorpus luteum antibody and menstrual irregularity in patients with systemic lupus erythematosus and Hashimoto's thyroiditis//Lupus. — 2005;14(8):618—624.
- Lim G.S., Petri M., Goldman D. Menstruation and systemic lupus erythematosus: a case-control study // Arthritis and Rheumatism. — 1993; 36(Suppl 5): R23.
- Appenzeller S., Blatyta P.F., Costallat L.T. Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes// Rheumatol Int. — 2008; 28(6):567—571.
- Mok C.C., Lau C.S., Wong R.W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. // Arthritis Rheum. —1998; 41(5):831—837.
- Shabanova S.S., Ananieva L.P., Alekberova Z.S. et al. Ovarian function and disease activity in patients with systemic lupus erythematosus // Clin Exp Rheumatol. — 2008; 26(3):436—441.
- Gomez F., de la Cueva R., Wauters J.P. et al. Endocrine abnormalities in patients undergoing long-term hemodialysis. The role of prolactin // Am J Med. — 1980; 68:522—530.
- Contreras G., Tozman E., Nahar N. et al. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide // Lupus. — 2005; 14 Suppl 1: 33—38.
- Velàsquez Méndez M.P., Ramirez Ruiz F.A., Vàsquez Duque G.M. et al. Prevalence of ovarian failure and risk factor in patients with systemic lupus erythematosus // Rev.Colomb.Reumatol. — 2006; 13(3):189—197.
- Насонова В.А., Иванова М.М., Самойлова С. Т. Материалы отчетной сессии Ин-та ревматизма АМН СССР за 1969 и 1970 гг. — М., 1971. 61.
- Ataya K.M., Valeriote F.A., Raniuhi-Ataya A.J. Effect of Cyclophosphamide on the Immature Rat Ovary// Cancer Research. — 1989; 49 (1): 1660—1664.
- Meirow D., Lewis H., Nugent D. et al. Sublinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool // Hum Reprod. — 1999; 14: 1903—1907.
- Manger K., Wildt L., Kalden J.R. et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study // Autoimmun Rev. — 2006; 5:269—272.
- Laskari K., Zintzaras E., Tzioufas A.G. Ovarianfunction is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil// Clin Exp Rheumatol. — 2010; 28(1):83—86.
- Houssiau F.A., Vasconcelos C., D'Cruz D. et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial oflow-dose versus highdose intravenous cyclophosphamide//Arthritis Rheum. — 2002; 46:2121—2131.
- Illei G.G., Austin H.A., Crane M. et al. Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis // Ann Intern Med. — 2001; 135:248—257.
- Frutos M.A., Martin Gómez A., de Ramón E. et al. Intravenous cyclophosphamide in lupus nephritis: twenty years reducing dose // Nefrologia. — 2007; 27(1):12—22.
- Henderson L., Masson P., Craig J.C. et al. Treatment for lupus nephritis (Review). The Cochrane Library. — 2012, Issue 12.
- Bertsias G.K., Tektonidou M., Amoura Z. et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis // Ann Rheum Dis. — 2012; 71(11):1771—1782.
- Langevitz P., Klein L., Pras M. et al. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis // Am J Reprod Immunol. — 1992; 28: 157—158.
- Boumpas D.T., Austin H.A., Vaughan E.M. et al. Risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy // Ann Intern Med. — 1993;119:366—369.
- McDermott E.M., Powell R.J. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide // Ann Rheum Dis. — 1996 Apr; 55(4):224—229.
- Серикова С.Ю., Козловская Н.Л., Шилов Е.М. Волчаночный нефрит как фактор риска атеросклероза у больных системной красной волчанкой// Тер. архив. — 2008; 6:52—58.
- Серикова С.Ю., Козловская Н.Л., Бобкова И.Н. Преждевременное развитие атеросклероза при системной красной волчанке: факторы риска // Клиническая нефрология. — 2013; 3:11—16.
- Bombardier C., Gladman D.D., Urowitz M.B. et al. Derivation of the SLEDAI: a disease activity index for lupus patients // Arthritis Rheum. — 1992; 35: 630—640.
- Wheeler C.A. Premature Ovarian Failure: treatment strategies // Journal of Reproduct. Immunol. — 1995; 76(5):130—131.
- Davis S.R. Premature Ovarian Failure//Мaturitas. — 1996; 23:1—18.
- Caulam C.B. Premature gonadal failure // Fertil Steril. — 1982; 38: 645—655.
- Ataya K., Pydyn E. Young J. et al. The uptake and metabolism of cyclophosphamide by the ovary // Sel Cancer Ther. — 1990; 6:83—692.
- Chapman R.M., Sutcliffe S.B. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin’s disease. // Blood. — 1981; 58:849—851.
- Longhi A., Pignotti E., Versari M. et al. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma // Oncol Rep. — 2003; 10:151—155.
- Dooley M.A., Nair R. Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease // Nat Clin Pract Rheumatol. 2008; 4(5):250—257.
- Somers E.C., Marder W., Christman G.M. et al. Use of a gonadotropinreleasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus//Arthritis Rheum. — 2005; 52: 2761—2767.
- Friedman A.J., Harrison-Atlas D., Barbieri R.L. et al. A randomized, placebocontrolled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata // Fertil Steril. — 1989; 51: 251—256.
- Peng C., Fan N.C., Ligier M. et al. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells // Endocrinology. — 1994; 135:1740—1746.
- Castelo-Branco C., Nomdedeu. Use of gonadotropinreleasing hormone agonists in patients with Hodgkin’s disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy//Fertil Steril. — 2007; 87: 702—705.
- Blumenfeld Z., Avivi I., Ritter M. et al. Preservation offertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women // J Soc Gynecol Invest. — 1999; 6:229 —239.
- Pereyra Pacheco B., Mendez Ribas J.M., Milone G. et al. Use of GnRH analogsfor functional protection of the ovary and preservation offertility during cancer treatment in adolescents: a preliminary report // Gynecol Oncol. — 2001; 81:391—397.
- Blumenfeld Z., Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr. — 2005; 34:40—43.
- Blumenfeld Z., Shapiro D., Shteinberg M. et al. Preservation offertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy // Lupus. — 2000; 9: 401—405.
- Danforth D.R., Arbogast L.K., Friedman C.I. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists//Fertil Steril. — 2005; 83:1333—1338.
- Meirow D., Assad G., Dor J. et al. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice // Hum Reprod. — 2004; 19:1294—1299.
Supplementary files
![](/img/style/loading.gif)